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As previously discussed (Whyatt et al. 2001),
experimental and human evidence indicates
that the developing fetus and neonate have
heightened susceptibility to certain chemical
carcinogens compared with the adult (reviewed
in Anderson et al. 2000; National Research
Council 1993). Factors that may increase fetal
susceptibility include higher rates of cell prolifer-
ation, the greater number of target cells at risk,
lower immunologic competence, and decreased
capacity to activate and detoxify carcinogens as
well as to repair DNA (Anderson et al. 2000;
National Research Council 1993).
Polycyclic aromatic hydrocarbons (PAHs)
are widespread pollutants commonly found
in ambient air, as well as workplace air, food,
and drinking water [International Agency for
Research on Cancer (IARC) 1983]. Incomplete
combustion of organic material is the major
source of PAHs. Airborne PAHs result mainly
from combustion of fossil fuels, tobacco prod-
ucts, and other organic materials. Generally,
emissions from motor vehicles and residential
heating are the major source of PAHs in
outdoor urban air, whereas environmental
tobacco smoke (ETS) is a major indoor source
(Donnenfeld et al. 1993; Lewtas 1994). A
number of PAHs, of which benzo[a]pyrene
(BaP) is a representative member, are trans-
placental carcinogens in experimental bioassays,
producing tumors in the liver, lung, lymphatic
tissues, and nervous system of the offspring
(Bulay and Wattenberg 1971; Rice and Ward
1982; Vesselinovitch et al. 1975). Experimental
animal studies have demonstrated that the
fetus and infant are more susceptible to PAH-
induced carcinogenesis than are adults (Rice
and Ward 1982; Soyka 1980; Toth et al.
1963; Vesselinovitch et al. 1975; Walters
1966). No comparable human data are avail-
able on age-related susceptibility to PAH car-
cinogenesis (Anderson et al. 2000). However,
epidemiologic studies have shown the human
fetus to be more sensitive than the adult to
the carcinogenic effects of drugs such as
diethylstilbestrol (Fraumeni 1974).
Biomarkers are biochemical or molecular
alterations that can document variation in sus-
ceptibility to carcinogens among human popu-
lations (Bearer 1998; Perera 2000; Whyatt et al.
2001). We have compared levels of biomarkers
in paired maternal and newborn blood samples
from a cohort of mothers and newborns in
New York City. Biomarkers were BaP-DNA
adducts in white blood cells (WBCs) measured
by high-performance liquid chromatography
(HPLC)–ﬂuorescence and plasma cotinine (an
internal dosimeter of cigarette smoke).
As an indicator of DNA damage, carcino-
gen-DNA adducts represent a critical step in
the carcinogenic pathway and are an informa-
tive biomarker of age-related susceptibility
and potential risk of cancer. The biologic
basis for measuring DNA adducts derives
from extensive experimental data supporting
their role in the initiation and possibly in the
progression of cancer (Perera 2000). An asso-
ciation between PAH-DNA adduct levels and
cancer risk has been seen previously in both
experimental and epidemiologic research
(Bartsch and Hietanen 1996; Poirier and
Beland 1992; Stowers and Anderson 1985;
Tang et al. 1995, 2001; Veglia et al. 2003).
PAHs cross the placenta. However, experi-
mental studies in laboratory animals using
radiolabeled PAHs indicate that the dose to
the fetus is generally at least an order of magni-
tude lower than the dose to paired maternal
tissues (Neubert and Tapken 1988; Srivastava
et al. 1986; Withey et al. 1993). In a number
of rodent bioassays, fetal levels of PAH-DNA
adducts have generally been higher than
expected, given the lower estimated trans-
placental dose of PAHs (Lu et al. 1986; Lu and
Wang 1990; Wang and Lu 1990). Similarly,
levels of micronuclei formation and DNA sin-
gle-strand breaks after transplacental PAH
exposure have been shown experimentally to
be higher in fetal than in paired maternal tis-
sues (Bolognesi et al. 1985; Harper et al.
1989; Wang and Lu 1990). A previous study
of a small number of maternal and cord blood
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Polycyclic aromatic hydrocarbons (PAHs) such as benzo[a]pyrene (BaP) are widespread air contami-
nants released by transportation vehicles, power generation, and other combustion sources.
Experimental evidence indicates that the developing fetus is more susceptible than the adult to carcino-
genic effects of PAHs, although laboratory studies in rodents suggest that the dose to fetal tissues is an
order of magnitude lower than that to maternal tissues. To assess fetal versus adult susceptibility to
PAHs and environmental tobacco smoke (ETS), we compared carcinogen-DNA adducts (a biomarker
associated with increased cancer risk) and cotinine (a biomarker of tobacco smoke exposure) in paired
blood samples collected from mothers and newborns in New York City. We enrolled 265 nonsmoker
African-American and Latina mother–newborn pairs in New York City between 1997 and 2001 (esti-
mated average ambient air BaP concentrations < 0.5 ng/m3). Despite the estimated 10-fold lower fetal
dose, mean levels of BaP-DNA adducts as determined by high-performance liquid
chromatography–ﬂuorescence were comparable in paired New York City newborn and maternal sam-
ples (0.24 adducts per 108 nucleotides, 45% of newborns with detectable adducts vs. 0.22 per 108
nucleotides, 41% of mothers with detectable adducts). However, by the Wilcoxon signed-rank test, the
levels in newborns were higher (p = 0.02). Mean cotinine was higher in newborns than in mothers (1.7
ng/mL, 47% detectable vs. 1.28 ng/mL, 44% detectable). Consistent with our prior study in a
Caucasian Polish population, these results indicate increased susceptibility of the fetus to DNA damage
and reduced ability to clear ETS constituents. The ﬁndings have implications for risk assessment, given
the need to protect children as a sensitive subset of the population. Key words: cancer, DNA adducts,
fetus, polycyclic aromatic hydrocarbons, susceptibility. Environ Health Perspect 112:1133–1136
(2004). doi:10.1289/ehp.6833 available via http://dx.doi.org/ [Online 22 March 2004]samples from a Chinese population found
comparable levels of PAH-DNA adducts
measured by competitive enzyme-linked
immunosorbent assay (ELISA) (Mumford
et al. 1993).
Cotinine is the major proximal metabolite
of nicotine but has a longer half-life in serum
(15–40 hr vs. 1–3 hr for nicotine). Cotinine
has been widely used as a specific marker of
exposure to tobacco smoke (Benowitz 1996),
which contains a myriad of carcinogens,
including PAHs and the nicotine-derived car-
cinogens 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK) and N´-nitrosonornicotine
(Brunnemann et al. 1996; Hoffmann et al.
1985; U.S. Public Health Service 1990). Like
nicotine, cotinine readily crosses the placenta
(Haddow et al. 1988; Lambers and Clark
1996; Sorsa and Husgafvel-Pursiainen 1988;
Ueda et al. 1989). The few studies comparing
cotinine levels in paired maternal–fetal samples
have given conflicting results (Donnenfeld
et al. 1993; Jauniaux et al. 1999; Luck et al.
1985; Mercelina-Roumans et al. 1996; Nafstad
et al. 1995).
We previously reported a detailed compari-
son of maternal–fetal biomarkers in a cohort
of 320 mothers and newborns, including
70 mother–newborn pairs from Krakow,
Poland (an industrial city with elevated ambi-
ent air pollution, including PAHs from coal
burned for industrial purposes and residential
heating) and 90 mother–newborn pairs from
Limanowa, Poland (a town located 70 km
southeast of Krakow with lower ambient pollu-
tion levels but 2-fold more frequent use of coal
stoves for indoor home heating) (Whyatt et al.
2001). That study reported that PAH-DNA
adducts measured by immunoassay were com-
parable in mothers and their newborns and
that PAH-aromatic adducts measured by
32P-postlabeling were significantly higher in
newborns than in mothers (Whyatt et al.
2001). Here we present results of analysis of
biomarkers in 530 New York City mothers
and newborns (265 pairs). The two popula-
tions (U.S. and Polish) represent an estimated
10- to 30-fold range of exposure to PAHs.
Materials and Methods
Study populations and biomarkers. Study sub-
jects are nonsmoking Dominican and African-
American women residing in Washington
Heights, Central Harlem, and the South
Bronx, New York, who delivered at New
York Presbyterian Medical Center, Harlem
Hospital, or their satellite clinics since February
1998, as previously described (Perera et al.
2003) (Table 1). Subjects signed a consent
form approved by the Columbia University
institutional review board. Race/ethnicity was
self-identiﬁed. Subjects were interviewed using
a questionnaire to elicit environmental and
health histories, including exposure to tobacco
smoke at home or work and dietary ingestion
of PAHs via smoked, fried, broiled, barbecued,
and grilled foods. Subjects included in the pre-
sent analysis are those with available PAH-
DNA adduct data for both mother and child.
Not all subjects in the ongoing parent study
(n = 474) had adduct data available because
assays are ongoing and in some cases the
amount of DNA was inadequate for analysis.
However, the present subset is representative of
the larger study cohort in that there were no
signiﬁcant differences between the present sub-
set and the overall cohort with respect to any of
the demographic and exposure variables shown
in Table 1. Maternal blood (30–35 mL) was
collected within 1 day postpartum, and umbili-
cal cord blood (30–60 mL) was collected at
delivery (Perera et al. 2003). Samples were trans-
ported to the laboratory immediately after col-
lection. The buffy coat, packed red blood cells,
and plasma were separated and stored at –70°C.
BaP-DNA adducts in extracted WBC DNA
were analyzed using the HPLC–fluorescence
method of Alexandrov et al. (1992), which
detects BaP tetraols. The assay gives zero values
when unexposed calf thymus DNA is tested
(D. Tang, personal communication). The
method has a coefﬁcient of variation of 12%
and a lower limit of detection of 0.25 adducts
per 108 nucleotides. HPLC analysis of DNA
samples for BaP-DNA adducts was performed
in batches, with 18-paired maternal and new-
born samples in the same batch. A portion of
each sample was shipped to the Centers for
Disease Control and Prevention for analysis of
cotinine using HPLC atmospheric-pressure
ionization tandem mass spectrometry, as previ-
ously described (Bernert et al. 2000). Current
data on annual average ambient concentrations
of BaP in New York City are not available.
However, outdoor 24-hr average BaP concen-
trations measured in U.S. urban areas have
generally been in the range of 0.5–4 ng/m3 in
recent years (U.S. EPA 1990). Personal air
monitoring of the New York City mothers for
48 hr during pregnancy provided data on
PAHs, including BaP (Perera et al. 2003). For
the ﬁrst 344 subjects analyzed, the average per-
sonal BaP concentration was 0.5 ng/m3 (range,
0.02–6.44). This may be an overestimate of
mean ambient exposure because personal moni-
toring can also reﬂect indoor sources such as
ETS. We estimate that the ambient BaP expo-
sure of the New York City cohort, and by infer-
ence their exposure to other related PAHs, was
at least 6- to 30-fold lower than that of the
Polish cohort (0.5 vs. 3–15 ng/m3).
Statistical analyses. Statistical analyses used
nonparametric methods because of the distrib-
utional properties of the biomarkers and
because many of the samples were below the
limit of detection. As in prior studies (Whyatt
et al. 2001), we assigned nondetectable samples
a value midway between the limit of detection
and zero. We used nonparametric methods
because the variables were not normally distrib-
uted. Spearman’s rank test was used to test cor-
relations between biomarkers in paired
maternal and newborn samples, whereas differ-
ences between biomarker levels in paired
maternal versus newborn samples were assessed
by the Wilcoxon signed-rank test. The variable
for ETS exposure was based on the presence of
smoker(s) in the home, and that for dietary
PAHs on frequency of consumption of fried,
broiled, or barbecued food. Associations were
considered signiﬁcant at p ≤ 0.05.
Results
The demographic characteristics of the
265 mother–newborn pairs from the New
York City cohort study are provided in Table
1. The mothers were all nonsmokers.
Detectable adduct levels were found in 42%
of mothers and 45% of newborns. Detectable
adducts were found in 53 (34%) newborns
whose mothers had nondetectable levels of
adducts; 43 (30%) mothers with detectable
adducts had newborns with nondetectable
levels of adducts (see Table 2). Levels of
adducts in paired newborn–maternal samples
were modestly but signiﬁcantly correlated (r =
0.28, p < 0.001), as were cotinine levels (r =
0.31, p < 0.001). DNA adducts were not sig-
nificantly correlated with cotinine in either
maternal (r = 0.07, p = 0.36) or newborn
(r = 0.05, p = 0.54) samples. ETS was signiﬁ-
cantly correlated with cotinine in both mater-
nal (r = 0.4, p < 0.001) and newborn (r = 0.4,
p < 0.001) samples. Dietary PAHs and ETS
were not signiﬁcantly associated with adducts
(p > 0.05), nor were adducts correlated with
PAHs in air monitored during pregnancy
(mothers: r = 0.01, p = 0.9; newborns: r = 0.02,
p = 0.8). Mean cotinine levels in mothers and
newborns were higher in African Americans
than in Dominicans, as was ETS exposure
(p < 0.05). However, mean adduct levels did
not differ between the two ethnic groups.
As shown in Table 3, the mean levels
of BaP-DNA adducts (per 108 nucleotides)
were comparable in New York City newborns
and mothers (0.24, 45% detectable in new-
borns vs. 0.22, 41% detectable in mothers).
However, by the Wilcoxon signed-rank test,
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Table 1. New York City cohort: number of mother–
newborn pairs,a maternal age, race/ethnicity, and
ETS exposure of mothers.
Characteristics Values
No. of mother–newborn pairs 265
Mother’s age [years (mean ± SD)] 24.5 ± 4.8
Race/ethnicity [no. of pairs (%)]
African American 102 (37.7)
Dominican 163 (62.3)
Self-reported ETS [no. of pairs (%)]
ETS exposure 100 (37.7)
No ETS exposure 165 (62.3)
aNumber of pairs with adduct data.the concentrations in newborns were sig-
nificantly higher than those in the mothers
(p = 0.02).
Cotinine levels were significantly higher
in newborns (1.7 per 108 nucleotides, 47%
detectable vs. 1.28 per 108 nucleotides, 44%
detectable; p < 0.001). Table 4 provides
details on the cotinine data.
Discussion
In a cohort of mothers and newborns from an
inner-city minority population in New York
City, given the lower estimated dose of PAHs
to the fetus, the levels of DNA damage from
PAHs in WBC were higher than expected in
newborns compared with paired mothers.
The results are consistent with our prior ﬁnd-
ing in a Polish cohort of 160 paired Caucasian
mothers and newborns (Whyatt et al. 2001)
that PAH-DNA adducts measured by ELISA
and PAH–aromatic adducts measured by
32P-postlabeling were significantly higher in
the newborns. Although the methods of adduct
analysis differed between the two studies, they
all reﬂect DNA damage from PAHs and related
aromatic compounds. Comparing the three
assays with respect to speciﬁcity to exposure,
the postlabeling method detects the broadest
spectrum of adducts (multiple PAHs and other
aromatic/hydrophobic compounds bound to
DNA); the ELISA detects BaP diol-epoxide
(DE)-DNA adducts and structurally related
PAH-DNA adducts; and the HPLC–ﬂuores-
cence method is the most speciﬁc (BaP-DNA
only). The results point to increased suscepti-
bility of the developing fetus to DNA damage
from this class of carcinogens. The lack of a
correlation between adducts and ETS, moni-
tored PAHs in air, or dietary PAHs probably
reflects the fact that adducts capture both
individual exposure and susceptibility.
There are no data in humans on maternal
versus fetal dose of PAHs. However, experi-
mental studies in rodents using radiolabeled
PAHs indicate that the dose to the embryo/
fetus is generally an order of magnitude or
more lower than the dose to paired maternal
tissues (Neubert and Tapken 1988; Srivastava
et al. 1986; Withey et al. 1993; reviewed in
Whyatt et al. 2001). Because humans and
rodents may not metabolize PAHs in the
same way, the data suggest, but do not prove,
that the human fetus also has differential
exposure. With this caveat, our ﬁndings sug-
gest that the amount of DNA damage per
unit dose of PAHs may be on the order of
10-fold higher in the fetus relative to the
mother. Increased susceptibility could result
from reduced detoxification capabilities or
decreased DNA repair capacity during fetal
development and may be an important factor
in the observed greater carcinogenic impact of
PAHs when administered to experimental
animals prenatally or neonatally compared
with later in life (Rice and Ward 1982; Soyka
1980; Toth et al. 1963; Vesselinovitch et al.
1975; Walters 1966).
Against the backdrop of the Polish study,
our present ﬁnding indicates heightened sus-
ceptibility of the fetus to PAH-DNA damage
over a wide range of BaP exposure (30-fold
range, from 0.5 to 15 ng/m3). This is of con-
cern in light of the association seen previously
in molecular epidemiologic research between
PAH-DNA adduct levels and cancer risk (Tang
et al. 2001). In a prior study of Polish new-
borns, an association has also been observed
between PAH-DNA adducts in cord blood and
adverse birth outcomes (Perera et al. 1998).
In the New York City cohort, as in the
Polish cohort, cotinine levels were signiﬁcantly
higher in newborn plasma compared with
paired maternal plasma. Few prior studies have
compared cotinine levels in mother–newborn
pairs and results have been conflicting
(Donnenfeld et al. 1993; Jauniaux et al. 1999;
Luck et al. 1985; Mercelina-Roumans et al.
1996; Nafstad et al. 1995). Our present results
in nonsmoking mothers and newborns suggest
that, like nicotine, cotinine concentrates in the
fetus (Lambers and Clark 1996; Luck et al.
1985). However, some of the differences we
observed between fetal and maternal samples
may have occurred because the maternal blood
Children’s Health | Biomarkers indicate susceptibility of the fetus
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Table 2. Adduct data for 265 mother–newborn pairs.
Mothers’ adduct levels
Newborns’ adduct levels Nondetectable Low detectable High detectable Total
Nondetectable
No. 103 25 18 146
Percent of newborns 70.5 17.1 12.3 100.0
Percent of mothers 66.0 53.2 29.0 55.1
Low detectablea
No. 25 15 15 55
Percent of newborns 45.5 27.3 27.3 100.0
Percent of mothers 16.0 31.9 24.2 20.8
High detectablea
No. 28 7 29 64
Percent of newborns 43.8 10.9 45.3 100.0
Percent of mothers 17.9 14.9 46.8 24.2
Total
No. 156 47 62 265
Percent of newborns 58.9 17.7 23.4 100.0
Percent of mothers 100.0 100.0 100.0 100.0
aThe cut point of low/high detectable was the median of the detectable level of adducts for mothers and newborns,
respectively.
Table 3. New York City cohort: biomarkers in paired maternal and newborn blood samples.
Mean ± SD (% detectable)
Maternal Newborn p-Value
WBC BaP-DNA adduct levels by 
HPLC–ﬂuorescence (per 108 nucleotides)
Total cohort (265 pairs) 0.22 ± 0.14 (41) 0.24 ± 0.15 (45) 0.02a
ETS exposure (100 pairs) 0.23 ± 0.16 (42) 0.24 ± 0.15 (44) 0.31
No ETS exposure (165 pairs) 0.21 ± 0.12 (41) 0.24 ± 0.15 (45) 0.08
Plasma cotinine (ng/mL)
Total cohort (160 pairs) 1.28 ± 9.77 (44) 1.7 ± 10.50 (47) < 0.001
ETS exposure (65 pairs) 3.04 ± 15.22 (69) 4.02 ± 16.27 (69) < 0.001
No ETS exposure (95 pairs) 0.08 ± 0.24 (26) 0.12 ± 0.48 (32) 0.001
aWilcoxon signed-rank test for paired samples comparing maternal and newborn levels.
Table 4. Cotinine data for 160 mother–newborn pairs.
Mothers’ cotinine levels
Newborns’ cotinine level Nondetectable Low detectable High detectable Total
Nondetectable
No. 81 3 1 85
Percent of newborns 95.3 3.5 1.2 100.0
Percent of mothers 90.0 8.3 2.9 53.1
Low detectablea
No. 9 26 2 37
Percent of newborns 24.3 70.3 5.4 100.0
Percent of mothers 10.0 72.2 5.9 23.1
High detectablea
No. 0 7 31 38
Percent of newborns 0 18.4 81.6 100.0
Percent of mothers 0 19.4 91.2 23.8
Total
No. 90 36 34 160
Percent of newborns 56.3 22.5 21.3 100.0
Percent of mothers 100.0 100.0 100.0 100.0
aThe cut point of low/high detectable was the median of the detectable level of adducts for mothers and newborns,
respectively.samples were collected on the day after deliv-
ery, whereas the newborn samples were col-
lected at delivery. We note, however, that
among 80 Polish mother and newborn pairs
whose blood samples were collected within
1 hr of each other the cotinine was signiﬁcantly
higher in the newborns (p < 0.05) (Whyatt
et al. 2001). Cotinine has low toxicity relative
to nicotine (Jordanov 1990; Lambers and
Clark 1996) but is a good internal dosimeter
for nicotine (Benowitz 1996). Concentration
of nicotine and cotinine in the fetus appears to
be caused by reduced clearance during fetal
development and by the fact that, in addition
to transfer from the maternal circulation, the
fetus is exposed from gastrointestinal reabsorp-
tion of the chemicals in swallowed amniotic
ﬂuid (Jauniaux et al. 1999). The adverse effects
of nicotine on fetal growth are well docu-
mented (Lambers and Clark 1996). In addi-
tion, like BaP, the nicotine-derived nitrosamine
NNK binds to DNA to form adducts (Hecht
1999) and is a potent transplacental carcinogen
in experimental bioassays (Jordanov 1990).
These ﬁndings highlight the need for pol-
lution and smoking prevention programs to
protect women of childbearing age and their
children from PAHs and ETS. Individuals are
generally exposed throughout most of their
life to low levels of carcinogens; if, in addi-
tion, they experience prenatal exposure to car-
cinogens, the possibility that they will develop
cancer over their lifetime may be dispropor-
tionately increased (Bulay and Wattenberg
1971). There are several possible factors
involved. First, as shown in our research, pre-
natal exposures apparently result in differen-
tially higher levels of procarcinogenic DNA
damage. Second, there is a higher probability
that low-level/long-latency effects will be
manifested as cancer during the individual’s
life span if these effects are initiated in utero
rather than later in life. Therefore, the results
presented here have implications for risk
assessment and environmental health policy
and highlight the need to protect pregnant
women and especially their children as a
sensitive subset of the population.
Conclusion
Consistent with a prior study in a Caucasian
Polish population, these results in a New York
City minority population indicate increased
susceptibility of the fetus to DNA damage and
reduced ability to clear ETS constituents. The
ﬁndings have implications for risk assessment,
given the need to protect children as a sensitive
subset of the population.
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